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SummAry
Sentinel node (Sn) biopsy of head and neck cancer is still considered investigational, and agreement on the width of the surgical sampling 
has not yet been reached. From may 1999 to Dec 2009, 209 consecutive patients entered a prospective study: 61.7% had primary tumour of 
the oral cavity and 23.9% of the oropharynx. Sn was not found in 26 patients. Based on these data and definitive histopathological analysis, 
we proposed six hypothetic scenarios to understand the percentage of neck recurrences following different treatments Among patients with 
identified Sn, 54 cases were pn+: 47 in Sn and 7 in a different node. Considering the six hypothetic scenarios: “only Sn removal”, “Sn 
level dissection”, “neck dissection from the tumour site to Sn level”, “selective neck dissection of three levels (SnD)”, “dissection from 
level i to iV” and “comprehensive i-V dissection”, neck recurrences could be expected in 6.5%, 3.8%, 2.18%, 2.73%, 1.09% and 1.09% of 
cases, respectively. Sn biopsy can be considered a useful tool to personalize the surgical approach to a n0 carcinoma. The minimum treat-
ment of the neck is probably dissection of the levels between the primary tumour and the level containing the Sn(s). outside the framework 
of a clinical study, the best treatment can still be considered SnD.
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riASSunTo
La biopsia del linfonodo sentinella (SN) nel carcinoma squamocellulare della testa e collo è ancora considerata investigazionale e non è 
stata raggiunta unanimità su quanto ampio debba essere il prelievo da utilizzare. In questo studio prospettico, dal maggio 1999 al dicembre 
2009, sono stati analizzati 209 pazienti consecutivi: 61,7% con tumore primitivo della cavità orale e 23,9% dell’orofaringe. Il SN non è 
stato identificato in 26 pazienti. Sulla base dei referti istopatologici definitivi, vengono creati sei scenari per ipotizzare quale sarebbe stato 
il tasso di ricorrenza nel collo se fossero stati impiegati i diversi trattamenti, più o meno invasivi. Dal totale di pazienti in cui è stato loca-
lizzato il SN, 54 casi sono stati pN+: 47 nel SN e 7 in un altro linfonodo. Considerando i sei scenari ipotetici: “rimozione solo SN”, “dis-
sezione livello contenente il SN”, “svuotamento laterocervicale dal sito del tumore al livello del SN”, “svuotamento selettivo di tre livelli 
(SND)”, “svuotamento dei livelli I-IV” e “svuotamento dei livelli I-V”, si sarebbero potute attendere rispettivamente 6,5%, 3,8%, 2,18%, 
2,73%, 1,09% e 1,09% di recidive nel collo. La biopsia del SN può essere considerato uno strumento utile per personalizzare l’approccio 
chirurgico di un carcinoma squamocellulare N0 della testa e collo. Il trattamento minimo del collo è probabilmente la dissezione dei livelli 
fra il tumore primitivo ed il livello che contiene SN(s). Al di fuori di studi clinici, il miglior trattamento rimane lo SND.
pArole ChiAVe: Svuotamento cervicale • Linfonodo sentinella • Carcinoma squamocellulare • Carcinoma testa e collo • Metastasi 
linfonodale
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Introduction
head and neck squamous cell carcinoma (SCC) has a 
high metastatic potential, and lymph node metastasis is 
one of the most significant prognostic factors: the pres-
ence of a single positive lymph node can reduces disease-
free survival at 5 years by 50% 1-7. Correct diagnosis and 
adequate treatment of the neck are crucial for determining 
prognosis. in recent decades, improved knowledge of the 
patterns of lymphatic drainage has allowed assessment of 
the levels at a higher risk of metastases for various pri-
mary sites, and therefore dissection can be limited to these 
levels. in the treatment of a n0 neck, the policy has shift-
ed from radical neck dissection to modified radical neck 
dissection (mrnD), and now to selective neck dissection Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: 10 years of experience
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(SnD) 8 9 10. Biopsy of the sentinel node (SnB) as a stag-
ing procedure and decision tool to establish whether sur-
gical treatment of the lymphatic area is to be performed or 
not is now recognized as the gold standard in melanoma 
and breast cancer. Although the methodology of SnB has 
been well known for more than 10 years and many pro-
spective studies with a significant number of patients have 
been published, it has not been accepted worldwide for 
head and neck SCC, where it is still considered investi-
gational. moreover, there is also debate regarding sites of 
primary tumour (T) and stages that could be eligible: at 
present, the general consensus is restricted to T1 and T2 
SCC of the oral cavity and the upper part of the orophar-
ynx. probably the most challenging issue is evaluation not 
only of the more uptaking single sentinel node (Sn), but 
of all the uptaking nodes and possible surrounding nodes: 
if they are multiple and at different levels, the procedure 
may eventually be the same as formal SnD. 
This paper will report the results of a single-centre series 
of SnB in head and neck SCC examining the feasibility 
and utility of the procedure. Furthermore, hypothesizing 
different scenarios, evaluation can be performed depend-
ing of different widths of surgical sampling. 
Patients and methods
From may 1999 to December 2009, 209 consecutive pa-
tients treated in the unit of otorhinolaryngology, Azienda 
ospedaliera Santa maria degli Angeli, pordenone (italy), 
were included in this prospective study after obtaining 
their informed consent.
eligibility criteria included histologically proven, previ-
ously untreated, SCC of the oral cavity, oropharynx, hy-
popharynx, larynx, scheduled for surgery (T + n) with 
either:
clinical c2n0 (i.e. degree 2 of certainty: clinical evalu- •	
ation always documented by CT scan) and candidates 
for monolateral or bilateral selective neck dissection, 
or
midline or paramedian T, monolateral neck disease and  •	
candidates for elective treatment of the contralateral 
neck.
The mean age of patients was 61 years, ranging from 36 to 
91 years, with a male:female ratio of 3:1. The tumour site 
was 61% in the oral cavity, 23% in the oropharynx, 8.6% 
in the larynx and 5.8% in the hypopharynx. moderate 
degree of tumour differentiation – g2 – was observed in 
54.5% of patients and g3 in 38.3%. Tumours were staged 
as T1 in 47 patients (22.5%), T2 in 100 (47.9%), T3 in 35 
(16.7%) and T4 in 27 (12.9%). one hundred and forty-
three patients (68.4%) were clinically staged as c2n0, 32 
(15.3%) as c2n1 and 24 (11.5%) as c2n2b.
The technique of injection and evaluation of the Sn is well 
known and has already been published also by our group 9 11.
none of the patients were candidates for removal of a 
single  node,  but  received  evaluation  of  the  Sn  within 
the context of some type of neck dissection. A mrnD 
was performed in 13 cases, SnD in 135, dissection of the 
level(s) containing the Sn in 39, dissection of the level(s) 
containing the Sn + SnD in 12 and a SnD (on the same 
side of the Sn) + mrnD (on the side of the paramedian 
tumour) in 10 patients. nodes were considered “sentinel” 
if the radioactivity level was at least 4 times over back-
ground level. The different levels of the neck nodes were 
carefully marked with threads during dissection, divided 
by the surgeon at the end of the procedure and sent to 
the pathologist in separate containers. if the Sn was not 
found, the patient was submitted to traditional treatment 
of the neck. even if in many patients intraoperative fro-
zen sections were examined, the present paper evaluates 
only the results of the definitive histopathologic workup 
with multiple serial sections and immunohistochemistry. 
recurrences were always assessed by CT scan and histo-
logically proven.
Combining clinical, histopathological data and the follow-
up of patients, with the aim to shed light on still-debated 
issues, six hypothetical scenarios were taken into consid-
eration: patients would be submitted to more or less ex-
tended surgical neck treatment to estimate the probability 
of neck recurrence.
Statistical analysis
A contingency table analysis between all considered vari-
ables and follow-up was done. A chi-square test based on 
the permutation technique was used. The results of the six 
scenarios were compared by a chi-square test based on 
permutation technique, Z test for proportions and Fisher’s 
exact test 12-14.
Results
Among the 209 patients, the Sn was not identified in 26 
cases, 11 in the first two years, 14 from the second to the 
fifth year and only one after five years. of the 183 patients 
with an identified Sn, histological analysis showed the 
presence of metastases in 54 cases, of which 47 were in 
the Sn and 7 in a different node in the same or adjacent 
level. of these 47 patients, other positive nodes were iden-
tified in the same level of the Sn in 10 cases, while addi-
tional metastatic nodes were present in a different level in 
another 10 patients. eight of these were in adjacent levels 
(1 above, 6 below and 1 case above and below) ( Fig. 1). 
in 129 patients (70.5%), the Sn was negative. in 5 cases 
(27%), the Sn was negative, but histological examination 
found an adjacent positive node in the same level, and in 
2 patients (1.1%) a positive node was found in adjacent 
levels (Fig. 1). An average of 1.86 Sn per patient were 
found.
no Sn was identified at level V and no pn+ was demon-
strated at level V. A Sn at level iV was detected in 8 pts: J.K. Antonio et al.
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6 had multiple Sns also identified in other levels, 2 had 
tumour in the floor of the mouth with isolated Sn at level 
iV but histologically negative. in patients with n0 neck 
and well lateralized tumour (> 1 cm from the midline), a 
Sn in the contralateral neck was identified in 3 cases (all 
histologically negative).
According to the protocol of adjuvant treatment in our 
hospital, 100 patients received postoperative radiothera-
py, and 10 also underwent concurrent chemotherapy. ra-
diotherapy was indicated for histopathological features of 
the tumour (involved or close surgical margins, poor dif-
ferentiation, angio-lymphatic or neural invasion), and for 
multiple positive nodes or with extra-capsular spread. in 
the present series, adjuvant treatment was indicated based 
on pn features in 51 patients,  even though it is our policy 
to irradiate both the bed of the tumour and node.
A total of 35 patients (16.7%) experienced relapse during 
follow-up (Table i). Among the 9 patients with relapse on 
n or n+m, four had relapse within 6 months of follow-up, 
3 patients from 6 months to 2 years and 2 patients after 2 
years. Among these 9 cases, only 5 had recurrence in the 
same side of Sn (the other 4 in the contralateral neck side, 
where the presence of n+ was known).
no relapse occurred in level V or in patients with SCC of 
oropharynx, larynx or hypopharynx.
of the 7 pts with recurrence in the same neck side of 
the Sn, 2 cases were associated with T relapse. The fol-
lowing analysis attempted to verify the reliability of Sn 
methods, provided that in these 2 cases the nodal relapse 
was not a growth of cells missed at the time of SnB, 
but colonization from the relapsed tumour, these cases 
are not further considered. on the other hand, if neck 
relapse allows for subsequent metastatic spread, the pa-
tient with nodal relapse and metastasis was considered 
in the analysis.
one hundred and forty-nine pts (71.3%) were followed-
up for longer than 2 years. At the time of writing, 68.4% 
of patients are free of disease (Fig. 2). 
Considering vital status, no statistical difference between 
men and women was found (Chi square = 2.25, p = 0.48) 
or among tumour sites (Chi square = 18.21, p = 0.013). 
patients  staged  as  pn+  had  the  worst  prognosis  (Chi 
square = 38.88, p = 0.001).
The sensitivity and specificity of the Sn method were, 
respectively, 87% and 100%; the false negative rate was 
5.1%. if we also consider the 5 patients with neck recur-
rence in the same side of the Sn, the sensitivity was 79.6% 
with a false negative rate of 8.5%.
on the basis of the available data, the following scenarios 
were considered to answer specific questions:
Scenario 1
How many patients would develop neck relapse if only the 
SN had been removed? How many patients would have 
neck relapse in the same side of the neck side as the SN?
if we consider the 183 patients in whom it was possible to 
identify the Sn, and we would have systematically done 
only Sn removal in patients in which the Sn was nega-
tive (at intra-operative or definitive histological analysis), 
we would have expected at least 12 recurrences. Five pa-
tients would have another positive node in the same level 
of Sn and another 2 patients would have positive nodes 
in adjacent levels. moreover, there were also 5 cases that 
developed neck metastases (Fig. 3): A case submitted to 
Fig. 1. Patients with localized SN.
Table I. Site of relapse.
Frequency Percentage Cumulative 
percentage
Relapse
No relapse 174 83.3 83.3
T 16 7.6 90.9
N 8 3.8 94.7
M 7 3.3 98.0
T+N 2 1.0 99.0
N+M 1 .5 99.5
T+M 1 .5 100.0
Total 209 100.0
A&F = Alive and free of disease; DT = Death for tumour; DST = Death for second 
tumour; DOD = Death for other disease; AWT = Alive with tumour; AWST = Alive 
with second tumour.
Fig. 2. Status of patients.Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: 10 years of experience
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Sn dissection (level ii right) that developed a late metas-
tases in level i. 
A patient with Sn identified on levels i and ii right (pn0) 
and level iV left (pn0) that was submitted to SnD (i-iV) 
on the left side and Sn dissection on the right side. This 
patient developed neck recurrence in level iii right.
A patient with Sn identified on levels i and iii right and 
level i left, submitted to SnD (i-iii) on the right side 
(pn0) and Sn level dissection on the left side (pn0). The 
relapse occurred in level i on the right side.
A case with Sn identified on levels i and ii left that was 
submitted to bilateral SnD. This patient developed recur-
rence in a parapharyngeal node on the left side. A patient 
with Sn identified on level i left that was submitted to dis-
section of only the Sn level. This patient developed neck 
recurrence in level iV left. Thus, if only Sn removal in 
patients with negative Sn had been performed, 12 recur-
rences (6.5%) could be expected.  
Scenario 2
with the hypothesis of some difficulties in precise iden-
tification of the single Sn and aiming to harvest a larger 
tissue sample containing the Sn, the entire neck level 
containing the Sn might be removed. How many patients 
would develop neck recurrence if only the entire level con-
taining the SN would have been dissected? How many pa-
tients have a negative SN but other positive nodes in other 
levels? How many patients would have neck recurrence in 
the same side of the SN?
if we consider all 183 patients in which it was possible 
to identify the Sn, and if we had only Sn level dissec-
tion in patients in which the Sn was negative, we would 
have expected at least 7 cases of relapse. Two patients had 
positive nodes in adjacent levels and 5 patients had neck 
recurrence, as previously described. in those cases, the re-
currence did not affect the Sn level but an adjacent level 
(Fig. 4).
Thus, if we had done only Sn level dissection, we would 
have expected 7 relapses (3.8%). 
Scenario 3
if the neoplastic cells migrate from the tumour to the Sn, 
one would argue that microscpic foci might be missed if 
all tissues between the tumour and node are not removed. 
The Sn procedure would have the aim of indicating how 
distant from the tumour one must arrive with the selective 
removal of neck levels.
How many patients would have developed neck recur-
rence if we had done neck dissection from the tumour site 
to SN level?
if we consider all 183 patients in which it was possible 
to identify the Sn, and if we had done neck dissection 
from the tumour site to Sn level in patients in which the 
Sn was negative, we should have expected at least 4 neck 
recurrences (2.18%): 
one patient with tumour in the oral cavity and Sn in lev-
els i and ii that developed neck relapse in level iii. 
one patient with a Sn identified on level i left that was 
submitted to dissection only at the level of the Sn. This 
patient developed neck relapse in level iV left.
one patient submitted to SnD (i-iii) who, despite this, 
developed a neck relapse in level i. 
Table II. Patients with relapse in the neck side of SN.
No. patients Primary site pT  Side of SN SN level pN Type of neck 
dissection
Side of the 
recurrence
Level of the 
recurrence
1 OC pT3 Bilateral I/II Left
None SN Right
pN+ SND Left Parapharynx
2 OC pT1 Right II Right pN0 SN level Right Level I
3 OC pT1 Bilateral I/II Right 
IV Left
pN0 SND (left side) 
+ SN level 
Right
Right Level III






5 OC pT1 Left I Left pN0 SN level Left Level IV
SND = Selective Neck Dissection; OC = Oral Cavity.
* The patients with neck recurrence in the contralateral neck or with recurrence in T+N have been excluded.
Fig. 3. Patients in scenario 1.J.K. Antonio et al.
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one patient submitted to SnD who developed neck re-
lapse (parapharynx).
in these latter two cases, neck recurrence could not have 
been avoided even with more extensive surgery.
Scenario 4
How many patients would have developed neck relapse 
if the usual SND of three levels for any tumour site was 
performed?
if we had performed traditional SnD (levels i-iii for oral cav-
ity and levels ii-iV for the pharynx and larynx) in 183 patients, 
we could have expected at least 5 neck relapses (2.73%):
Two patients with tumour in the oropharynx who had a  •	
positive node in level i (both identified by Sn method).
Two patients submitted to SnD that developed neck re- •	
lapse on level i and parapharyngeal nodes. 
one patient with Sn identified on level i left and sub- •	
mitted to dissection of the Sn level only. This patient 
developed neck relapse in level iV left.
Scenario 5
How many patients would have developed neck relapse if 
we had always done dissection from level I to level IV?
if we had used the neck dissection from level i to level iV 
in the 183  patients, we could have expected at least two 
neck relapses (1.09%):
Two patients submitted to SnD that developed neck re- •	
lapse on level i and parapharyngeal nodes. 
Scenario 6
How many patients would have developed neck relapse if 
we had always done dissection from level I to level V?
if we had used comprehensive mrnD (level i-V) for the 
183 patients, we could have expected at least 2 neck re-
lapses (1.09%):
Two patients submitted to SnD that developed neck re-
currence on i level i and parapharyngeal nodes. 
no neck recurrence was observed on level V.
using  scenarios  4,  5  or  6,  we  would  have  dissected 
many”disease  free”  levels:  if  we  compare  these  possi-
bilities with “scenario 3”, we would have dissected more 
(1.26, 2.10 and 3.43) levels/patient, respectively, in sce-
narios 4, 5 and 6. 
Tab. 3 shows the significant differences in relapse rate 
among  the  various  scenarios:  there  was  no  difference 
between scenario 1 and 2 using any statistical method; 
however, there was a difference between scenario 1 and 
scenarios 5 or 6. only the Chi square method showed a 
significant difference between scenarios 2 and 5 or be-
tween scenarios 2 and 6 (Table iii).
Discussion
Between the routine use of elective neck dissection in all 
n0 neck and a “wait and see” policy, SnB in hnSCC 
has been suggested as a method to improve the accuracy 
of staging and tailor treatments. Furthermore functional 
outcome after SnB is recognized as significantly better 
compared to SnD 15, even if the quality of life perceived 
from the patients is similar  16. nevertheless, we should not 
forget that we are dealing with a group of patients with a 
good prognostic factor, namely a n0 neck. Therefore, all 
our efforts to improve the quality of life must not affect 
prognosis. 
Although in melanoma and breast cancer the Sn proce-
dure is widely employed, for SCC of the head and neck 
the most active proponents state that it is “safe and ac-
curate with… the potential to become the new standard 
of care” 17.
The first data worthy of note in the present series is the ab-
sence of either pn+ or relapse in level V, further confirm-
ing that in c2n0 pts with SCC of the oral cavity, oro and 
hypo-pharynx and larynx, elective treatment of level V is 
unnecessary. A second consideration is that unexpected 
lymphatic drain arriving from the site of the tumour to 
distant levels is very rare: in this series, no metastatic cells 
were found in the contralateral neck of lateralized tumours 
and no isolated metastases occurred at level iV.
The technique of Sn was started in our hospital 10 years 
ago within the collaborative framework of a multidiscipli-
nary team. At the beginning, the Sn was not identified in 
a quite high percentage of patients: the common learning 
curve 1 18 19 was particularly prolonged in our hands and 
these patients were treated with mrnD. perhaps one of 
the more rewarding results is the assembly of a interested, 
motivated and efficient team.
Another fact to note is the feasibility and safety of the 
technique in tumours of the larynx, oropharnyx and hy-
popharynx and for study of the contralateral neck in pa-
tients with a paramedian tumour and homolateral n+: no 
relapse on the Sn side was observed in these cases, but the 
small number of patients must be considered as a source 
of possible bias. even if the majority of studies on SnB 
are focused on the oral cavity and oropharynx with n0, 
nevertheless some authors also consider different tumour 
sites and nodal classes  20 21. we chose to include laryn-
geal and hypopharyngeal SCC to evaluate the feasibility 
of the procedure even in these cases; the small number 
of patients enrolled is due to the large number of non-
surgical protocols usually adopted for these localizations 
Fig. 4. Patients in scenario 2.Sentinel lymph node biopsy in squamous cell carcinoma of the head and neck: 10 years of experience
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in our hospital. likewise, as for other studies of SnB in 
the literature 22-26, herein SnB was also performed in the 
same context of a neck dissection: this was not a limiting 
factor, but provided better safety and more information 
about adjacent nodes.
of the 183 patients in whom Sn was identified, in 5 (2.7%) 
it was histologically negative, whereas a metastatic node 
was found in an adjacent node in the same level. The posi-
tivity of a node different from the ‘‘hottest’’ reach 13% 
in the experience of gallegos-hernadez 22 may be related 
to the difficulty in identifying the Sn, and may suggest 
the indication to dissect the entire level containing the 
Sn. however, this is not the opinion of the authors who 
consider that non-sentinel nodes should be removed only 
if they represent a “hurdle” for Sn resection 8. Different 
radioactivity uptake thresholds have been suggested to 
determine the indication for tissue removal, either 3 or 4 
times the background or more than 10% of background 1 27, 
or more than one-tenth of the hottest node8. The question 
of how many Sns must be removed if they are multiple 
and at different levels is still unanswered, and may lead 
to an extensive procedure that is not very different from 
a formal SnD. werner advocates biopsy of 1 to 3 “hot” 
lymph nodes to reduce the possibility of false-negative 
results 28, and Atula 29 also judges that only the three hot-
test nodes require sampling to stage the neck accurately. 
Following gallegos-hernandez, if more than two Sn are 
identified and examined, there are fewer probabilities of 
having positive non-sentinel nodes  24. Furthermore, one 
may speculate that the presence of a Sn in levels distant 
from the tumour would suggest the possibility of distant 
metastatic cells that might be neglected between the tu-
mour and node. one possibility would be to limit SnD 
from the site of the tumour to the level of the identified 
Sn,  also  removing  the  intervening  levels  (scenario  3), 
which may minimize the risk of regional recurrence to the 
percentage seen with formal SnD.
of the 47 patients with a positive Sn, we observed 10 cas-
es with the presence of other positive nodes at the same 
Sn level and 10 cases at other levels, adjacent or not, but 
never at level V. This may suggest the indication of per-
forming a dissection of all levels in patients with a posi-
tive Sn, in agreement with the opinion of other authors 30, 
possibly sparing level V. Burns reports that the number of 
metastases to level V would be very low for the oral cavity 
and oropharynx, even in patients with a positive Sn, and 
that the comprehensive dissection is thus unnecessary 16. 
Some previous studies have advocated using SnB only 
for n0 pts and for early T 31 32, as.used outside these cir-
cumstances, SnB may cause errors and inconsistencies. 
in addition, large tumours would hardly be surrounded 
by radiotracer and would drain to multiple lymphatic ba-
sins  8 31. we use the technique for negative sides of the 
neck, even in larger tumours and have not found any ma-
jor difficulties. The use of SnB is also possible in patients 
with tumours close to the midline, with one clinically 
positive side, where it is necessary to clarify the actual 
need of contralateral dissection. in this case, there is still 
no consensus on the best option, and certainly Sn can be 
of assistance 11. prognosis of patients is poor if the Sn is 
Table III. Significance of differences of relapse between the scenarios using Chi Square Test based on permutation technique, Z test for proportions 
and Fisher’s exact test.
Scenario Chi Squared Z Test Fisher’s Exact Test
Chi Squared Value Probability Z Value Probability %
1X2 1.39 p = 0.140 0.94 65.0 p = 0.34
1X3 4.18 p = 0.006 1.78 92.6 p = 0.07
1X4 3.00 p = 0.024 1.49 86.4 p = 0.13
1X5 7.42 p = 0.000 2.45 98.6 p = 0.01
1X6 7.42 p = 0.000 2.45 98.6 p = 0.01
2X3 0.83 p = 0.290 0.61 46.0 p = 0.54
2X4 0.34 p = 0.532 0.30 61.7 p = 0.77
2X5 2.84 p = 0.028 1.36 82.5 p = 0.17
2X6 2.84 p = 0.028 1.36 82.5 p = 0.17
3X4 0.11 p = 0.726 0.01 0.30 p = 1.00
3X5 0.67 p = 0.361 0.42 32.0 p = 0.68
3X6 0.67 p = 0.361 0.42 32.0 p = 0.68
4x5 1.39 p = 0.140 0.76 55.0 p = 0.44
4X6 1.39 p = 0.140 0.76 55.0 p = 0.44
5X6 0.00 p = 1.00 0.00 0.00 p = 1.00 
* Bold identifies significant probability.J.K. Antonio et al.
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histologically metastatic (pn+) 32, compared to pn-, but 
this is in agreement with the general consensus that pn- 
have better outcomes than pn+.
The sensitivity of the method in the present study was sat-
isfactory (87%), with a false negative rate of 5.2%. Today, 
after years of experience in several centres, with improve-
ments in the method, it is accepted that the percentage of 
false-negative Sn should be below 5% 8. Considering the 
suggested scenarios, even if these are purely hypothetical 
conditions, this data can be compared with the possible 
regional recurrence rate with the more recent literature 
and with data from our previous experience.
regional recurrences are reported after elective dissec-
tion of a n0 neck by the meta-analysis of Fasunla 33 in 
6-30% of cases, by liu 34 in 14.8%, by ebrahimi 35 in 7% 
and by Deganello 36 in 6.25%. in a previous analysis of 
comprehensive neck dissection, we  37 reported regional 
recurrences in 3.2% (8/250) of cases after elective dis-
sections; in a subsequent report of elective SnD, we had 
only 1/310 isolated nodal recurrence (unpublished data, 
presented at round Table elective neck Treatment at Sio 
Annual meeting, Bologna 2006).
in the hypothesis that only Sn would be resected (Sce-
nario 1), the probability of neck relapse would be 6.5%. 
Comparing Scenario 2 to the other scenarios, i.e. where 
we would have hypothetically made dissection from the 
tumour to the level of Sn (Scenario 3), performed SnD 
(Scenario 4), made dissection from level i to iV (Scenario 
5) or systematically dissected from level i to V (Scenario 
6), the only statistical difference as between scenario 2 
and 5 or scenario 2 and 6, which are obviously safer, al-
though more extended. 
more extended surgery means a considerable number of lev-
els will be unnecessarily dissected, in addition to longer sur-
gical time, higher costs and greater morbidity. postoperative 
morbidity should not be disregarded if it does not add a sig-
nificant advantage. Functional outcomes after SnB are rec-
ognized as significantly better than after SnD. however, this 
is not reflected in the score of quality of life questionnaires 15, 
and the perception of the patient is probably as important 
as all functional items. A convenient compromise for n0 
patients needing elective neck treatment may be dissection 
from the site of tumour to the level containing the Sn(s).
Conclusions
SnB is technically feasible, and after the initial acquisi-
tion of experience by a multidisciplinary team can be safe-
ly used. nevertheless, the role of SnB in hnSCC is still 
undecided. Surgeons should be aware that these patients 
have a n0 neck and good prognosis, and that elective SnD 
has proven reliability and worldwide acceptance. The Sn 
concept defines the surgical approach to a n0 neck, tailor-
ing the dissection on the lymphatic drainage pattern to the 
specific patient.
The  minimum  investigational  treatment  of  the  neck  is 
likely to be dissection of the levels from the site of tumour 
to the level containing the Sn(s). At any rate, while await-
ing the results of large prospective studies, clearly dem-
onstrating the utility of the procedure as for the cutaneous 
melanoma, the definitive practical conclusion should be 
left to the surgeon who may consider risks and benefits 
faced by the individual patient with head and neck n0 
cancer.
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